The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 30, 2026

Filed:

Apr. 02, 2021
Applicants:

Beigene, Ltd., San Mateo, CA (US);

Springworks Therapeutics, Inc., Stamford, CT (US);

Inventors:

Lusong Luo, San Mateo, CA (US);

Zhiyu Tang, San Mateo, CA (US);

Badreddin Edris, Stamford, CT (US);

Todd Webster Shearer, Stamford, CT (US);

Assignees:

SPRINGWORKS THERAPEUTICS, INC., Stamford, CT (US);

BEIGENE, LTD., San Mateo, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/4375 (2006.01); A61K 9/48 (2006.01); A61K 31/166 (2006.01); A61P 11/00 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4375 (2013.01); A61K 9/4858 (2013.01); A61K 9/4866 (2013.01); A61K 31/166 (2013.01); A61P 11/00 (2018.01); A61P 35/00 (2018.01);
Abstract

The present disclosure relates to methods of treating cancers comprising coadministration of mirdametinib or a pharmaceutically acceptable salt form thereof, and lifirafenib or a pharmaceutically acceptable salt form thereof, to a patient in need thereof. Also disclosed are pharmaceutical compositions of mirdametinib or a pharmaceutically acceptable salt form thereof, and lifirafenib or a pharmaceutically acceptable salt form thereof, for use in such cancer treatment, as well as uses of these compounds for manufacture of medicaments for the treatment of cancers.


Find Patent Forward Citations

Loading…